Panelists discuss how the SUNLIGHT trial’s success stems from its methodical design with robust single-arm and randomized phase two data that earned NCCN guideline inclusion before the phase three study, comprehensive quality of life data collection, and straightforward methodology, while acknowledging that the absence of consensus definitions for clinically meaningful outcomes in refractory metastatic colorectal cancer forces providers to rely on individual thresholds when evaluating hazard ratios, confidence intervals, and safety profiles, with the additional challenge that different organizational frameworks (ASCO, ESMO) use varying criteria for progression-free survival and overall survival endpoints, making consistent trial interpretation difficult without standardized consensus definitions.